Advanced Filters
noise

dermatitis-atopic Clinical Trials

A listing of dermatitis-atopic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 183 clinical trials
M Maria Beatrice De Felici Del Giudice

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Atopic dermatitis is an ongoing condition that causes skin irritation, redness, and itchiness. Treatments are usually topical - applied to the skin (e.g., moisturisers or medicated creams) - but a wider variety of systemic treatments (that target the whole body) are needed for those whose condition does not improve with …

18 - 100 years of age Both Phase 3
S Stephanie Rangel

Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)

The study is a sequentially recruited, cross-over-cohort, outpatient-based evaluation of the effectiveness of wool clothing, as compared to standard clothing, in reducing the severity of childhood atopic dermatitis (eczema) over two consecutive six-week periods.

3 - 5 years of age Both Phase N/A
J Jianzhong Zhang

Evaluate the Safety, Tolerability of BAT6026

This is a Phase IB/IIA clinical study of BAT6026 in patients with AD. The subjects were adults with moderate to severe atopic dermatitis (AD) whose disease was not adequately controlled by prior topical medications or for which topical medications were not appropriate. The first phase was the phase IB study, …

18 - 75 years of age Both Phase 1/2

NMF-CsA-Dupi Trial

The goal of this study is to investigate whether stratification of children with atopic dermatitis on the NMF biomarkers results in an improvement of effectiveness and efficiency in the use of systemic treatment (ciclosporin and dupilumab) in moderate-to-severe atopic dermatitis.

2 - 18 years of age Both Phase N/A

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD). The purpose of this study is to compare the immune …

18 - 100 years of age Both Phase 2

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

This is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss (TEWL) before and after skin tape stripping (STS) in approximately 48 pediatric participants (aged ≥6 and <15 …

6 - 14 years of age Both Phase 4

The Study of CM326 in Moderate-to-severe Atopic Dermatitis

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CM326 in moderate-severe atopic dermatitis subjects.

18 - 75 years of age Both Phase 2

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).

2 - 12 years of age Both Phase 2
Q Qianjin Lu

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.

18 - 75 years of age Both Phase 2
Y Yuling Shi, MD

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

18 - 70 years of age Both Phase 1

Rewrite in simple language using AI